Skip to Content

Equetro Shire Pharmaceuticals Group plc - Treatment for Bipolar Disorder

Equetro, previously known as SPD417, is indicated for the treatment of acute manic and mixed episodes associated with Bipolar I Disorder. Equetro will be available for prescribing in the US in the first quarter of 2005.

Posted: December 2004

Equetro (carbamazepine) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.